Results 1 to 10 of about 147,781 (115)
Overview of Research into mTOR Inhibitors [PDF]
Molecules, 2022 The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family.
Pan Zhao, Dong-Sheng Zhao
exaly +4 more sources
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Pharmaceutics, 2021 The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various ...
Anupam Bishayee +2 more
exaly +3 more sources
The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients [PDF]
VirusesBackground: Heart failure (HF) remains a major global health challenge, with orthotopic heart transplantation (OHT) serving as the gold-standard therapy for end-stage disease.
Agnieszka Kuczaj +8 more
doaj +2 more sources
Pharmacological mTOR inhibitors in ameliorating Alzheimer’s disease: current review and perspectives [PDF]
Frontiers in PharmacologyTraditionally, pharmacological mammalian/mechanistic targets of rapamycin (mTOR) kinase inhibitors have been used during transplantation and tumor treatment.
Pei-Lun Xie +4 more
doaj +2 more sources
Cancer and mTOR inhibitors in kidney transplantation recipients [PDF]
PeerJ, 2018 Background Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known.
Chih-Chin Kao +8 more
doaj +2 more sources
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
Frontiers in Pharmacology, 2022 The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway.
Xianbo Wu +7 more
doaj +1 more source
Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approaches. [PDF]
PLoS ONE, 2014 BACKGROUND: Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism, and angiogenesis. Thus, there is a great deal of interest in developing clinical drugs based on mTOR.
Ling Wang +5 more
doaj +1 more source
Current Research in Pharmacology and Drug Discovery, 2022 The mammalian target of rapamycin (mTOR) plays an important role in the aggressiveness and therapeutic resistance of many cancers. Targeting mTOR continues to be under clinical investigation for cancer therapy.
David Danielpour +3 more
doaj +1 more source
Neurology and Therapy, 2023 Introduction Mechanistic target of rapamycin (mTOR) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous ...
Dominika Śmiałek +3 more
doaj +1 more source
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. [PDF]
PLoS ONE, 2013 BACKGROUND:Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation.
Costanza Bogani +7 more
doaj +1 more source